Kangchuanji 2020 New Year Annual Meeting Concludes Successfully
2022-09-12
On January 18, 2020, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. held its 2019 Year-End Summary Conference and 2020 New Year Annual Meeting. Under the theme "Stay True to Our Original Aspirations, Move Forward with Determination," the event featured the year-end summary, an awards ceremony recognizing outstanding achievements, and team morale presentations. Each department presented ten wonderful performances. After the performances, everyone raised their glasses together and enjoyed a sumptuous dinner. Amidst laughter and joy, the Kangchuanji 2020 New Year Annual Meeting came to a successful close.
Keywords:
Related information
From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.
2026-08-04
On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.
2024-10-27
Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).
2026-07-03